GlycaNova’s patents and trademarks protect the company’s technology and form the foundation for commercial development within both the nutraceutical and pharmaceutical areas.

IPO Lentinex/Immuna

A brief summary of Glycanova patent rights covering Lentinex and Immuna – irrespective of the formulation of the product – as well as methods for making or using Lentinex is given below:

P203 Patent Family – based on WO 2003/020944

United States
US 8,758,768 is a United States patent directed to a method for producing Lentinex by liquid cultivation of Lentinula edodes.

Europe
EP 02762662 is a European patent application directed to a method for producing Lentinex by liquid cultivation of Lentinula edodes. Patent protection may be extended to Hong Kong following issuance of a European Patent.

P204 Patent Family – based on WO 2006/007848

United States
US 7,514,085 is a United States patent directed to Lentinex produced by liquid cultivation of Lentinula edodes.

US 7,682,615 is a United States patent directed to Lentinex produced by liquid cultivation of Lentinula edodes.

Europe
EP 05758000 is a European patent application directed to Lentinex produced by liquid cultivation of Lentinula edodes. Patent protection may be extended to Hong Kong following issuance of a European Patent.

China
ZL 200580030988.5 is a Chinese patent directed to Lentinex produced by liquid cultivation of Lentinula edodes.

Japan
JP 5502830 is a Japanese patent directed to Lentinex produced by liquid cultivation of Lentinula edodes.

Thailand
TH 0501003258 is a patent application in Thailand covering Lentinex produced by liquid cultivation of Lentinula edodes.

Canada
CA 2,574,060 is a Canadian patent application directed to Lentinex produced by liquid cultivation of Lentinula edodes.

South Africa
ZA 2007/00730 is a South African patent application covering Lentinex produced by liquid cultivation of Lentinula edodes.

P206 Patent Family – based on WO 2006/133707

United States
US 11/917,521 is an allowed United States patent application covering a pharmaceutical kit of parts comprising Lentinex and an anti-cancer medicament.
US 14/705,346 is a United States continuation patent application covering a pharmaceutical kit of parts comprising Lentinex and an anti-cancer medicament.

Europe
EP 06742465 is a European patent application covering the use of Lentinex and an anti-cancer medicament for the treatment or prophylaxis of cancer. Patent protection may be extended to Hong Kong following issuance of a European Patent.

IPR – Ganodex

P203 Patent Family – based on WO 2003/020944

United States
US 14/162,272 is a US patent application directed to a method for producing Ganodex by liquid cultivation of Ganoderma lucidum.

Europe
EP 02762662 is a European patent application. It is in principle possible to file a divisional patent application in Europe essentially directed to the subject matter presently claimed in US 14/162,272.

P204 Patent Family – based on WO 2006/007848

Europe
EP 05758000 is a European patent application directed to Ganodex as produced by liquid cultivation of Ganoderma lucidum. Patent protection may be extended to Hong Kong following issuance of a European Patent.

Japan
JP 2011-233448 is a Japanese patent application directed to Ganodex as produced by liquid cultivation of Ganoderma lucidum.

Thailand
TH 0501003258 is a patent application in Thailand covering Ganodex as produced by liquid cultivation of Ganoderma lucidum.

India
IN 546/DELNP/2007 is an Indian patent application directed to Ganodex as produced by liquid cultivation of Ganoderma lucidum.
IN 5068/DELNP/2014 is an Indian patent application covering Ganodex as produced by liquid cultivation of Ganoderma lucidum.

South Africa
ZA 2007/00730 is a South African patent application covering Ganodex as produced by liquid cultivation of Ganoderma lucidum.

P228 Patent Family – based on WO 2014/122627
PCT/IB2014/058878 is an international patent application, the claims are directed to a composition for treatment of a skin disease, including a Ganodex composition comprising beta glycan polysaccharides obtained from the aqueous, liquid growth medium of a liquid culture of Ganoderma lucidum.

P206 Patent Family – based on WO 2006/133707
Patent applications are presently pending in the United States and in Europe in this patent family. The claims of the PCT-application are directed to a kit-of-parts comprising an anti-cancer medicament and a Basidiomycete bioactive agent, including bioactive agents obtained from Ganoderma lucidum following liquid cultivation thereof.